Cassava Sciences | PTIE - Current Assets


Cassava Sciences reported $108.91M in Current Assets for its fiscal quarter ending in September of 2025.





Current Assets Change Date
Abbott USD 26B 1.16B Dec/2025
Amgen USD 29.06B 1.17B Dec/2025
Biogen USD 8.97B 37.5M Dec/2025
Cara Therapeutics USD 43.13M 4.18M Jun/2025
Cassava Sciences USD 108.91M 5.91M Sep/2025
Eisai JPY 840.88B 50.18B Dec/2025
Eli Lilly USD 55.63B 6.44B Dec/2025
Geron USD 522.34M 16.75M Sep/2025
J&J USD 55.62B 1.01B Dec/2025
Merck USD 47.56B 10.49B Sep/2025
Novartis USD 28.2B 2.26B Sep/2025
Novavax USD 974.59M 55.08M Sep/2025
Pfizer USD 46.92B 3.22B Sep/2025
Roche Holding CHF 38.73B 3.03B Dec/2025